Martin, T. G., Shah, N., Richter, J., Vesole, D. H., Wong, S. W., Huang, C., . . . Chari, A. (2021). Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer.
Stile di citazione ChicagoMartin, Thomas G., et al. "Phase 1b Trial of Isatuximab, an Anti‐CD38 Monoclonal Antibody, in Combination With Carfilzomib As Treatment of Relapsed/refractory Multiple Myeloma." Cancer 2021.
Citazione MLAMartin, Thomas G., et al. "Phase 1b Trial of Isatuximab, an Anti‐CD38 Monoclonal Antibody, in Combination With Carfilzomib As Treatment of Relapsed/refractory Multiple Myeloma." Cancer 2021.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.